Results 141 to 150 of about 3,492,883 (216)

Targeting focal adhesion kinase overcomes erlotinib resistance in smoke induced lung cancer by altering phosphorylation of epidermal growth factor receptor

Oncoscience, 2018
EGFR-based targeted therapies have shown limited success in smokers. Identification of alternate signaling mechanism(s) leading to TKI resistance in smokers is critically important.
Hitendra S Solanki, R. Raja, A. Zhavoronkov, I. Ozerov, Artem V. Artemov, Jayshree Advani, A. Radhakrishnan, Niraj Babu, Vinuth N. Puttamallesh, Nazia Syed, Vishalakshi Nanjappa, Tejaswini Subbannayya, Nandini A. Sahasrabuddhe, Arun H. Patil, T. K. Prasad, Daria A. Gaykalova, Xiaofei Chang, Rachana Sathyendran, P. P. Mathur, A. Rangarajan, D. Sidransky, A. Pandey, E. Izumchenko, H. Gowda, Aditi Chatterjee   +24 more
semanticscholar   +1 more source

PDZK1 suppresses TNBC development and sensitizes TNBC cells to erlotinib via the EGFR pathway

Cell Death and Disease
Epidermal growth factor receptor (EGFR)-targeted drugs (erlotinib, etc.) are used to treat multiple types of tumours. EGFR is highly expressed in most triple-negative breast cancer (TNBC) patients.
Yuanzhen Ma, Zhiyu Fang, Hongning Zhang, Yijun Qi, Yuke Mao, Junfang Zheng   +5 more
doaj   +1 more source

pSTAT3 transactivates EGFR in maintaining EGFR protein homeostasis and EGFR-TKI resistance

Acta Biochimica et Biophysica Sinica
EGFR protein trafficking is critical for regulating multiple biological processes, including cell growth and survival. However, how EGFR protein homeostasis is maintained remains unclear.
Ao Juan, Fei Junjie, Wang Guoqiang, Zhang Wenhua, Yu Shuhan, Guo Rongtian, Niu Mengmeng, Chen Hu, Cao Yang, Xiao Zhi-Xiong Jim, Yi Yong   +10 more
doaj   +1 more source

The characterization, management, and future considerations for ErbB-family TKI-associated diarrhea. [PDF]

, 2019
PurposeDiarrhea is recognized as a common adverse event associated with tyrosine kinase inhibitors (TKIs), with those targeting the ErbB family of receptors being associated with the highest rate of diarrhea.MethodsThis paper reviews data on the ...
Bosserman, Linda, Bryce, Richard, Di Palma, Jack A, Moran, Susan, Olek, Elizabeth, Rugo, Hope S, Tripathy, Debu   +6 more
core  

LncRNA MALAT-1 modulates EGFR-TKI resistance in lung adenocarcinoma cells by downregulating miR-125

Discover Oncology
Molecular targeted therapy resistance remains a major challenge in treating lung adenocarcinoma (LUAD). The resistance of Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs, epidermal growth factor receptor-tyrosine kinase inhibitor ...
Jie Luo, Qiaoya Ren, Xiaoxi Liu, Qian Zheng, Ling Yang, Mi Meng, Hu Ma, Sisi He   +7 more
doaj   +1 more source

Interleukin-1 blockade overcomes erlotinib resistance in head and neck squamous cell carcinoma

OncoTarget, 2016
Erlotinib has demonstrated poor clinical response rates for head and neck squamous cell carcinoma (HNSCC) to date and the majority of respondents acquire resistance to erlotinib relatively quickly.
Aditya Stanam, K. Gibson-Corley, L. Love-Homan, Nnamdi Ihejirika, Andrean L. Simons   +4 more
semanticscholar   +1 more source

Upstream and Downstream Co-inhibition of Mitogen-Activated Protein Kinase and PI3K/Akt/mTOR Pathways in Pancreatic Ductal Adenocarcinoma

Neoplasia: An International Journal for Oncology Research, 2016
BACKGROUND: Extensive cross talk exists between PI3K/Akt/mTOR and mitogen-activated protein kinase (MAPK) pathways, and both are upregulated in pancreatic ductal adenocarcinoma (PDAC).
Matthew H. Wong, Aiqun Xue, Robert C. Baxter, Nick Pavlakis, Ross C. Smith   +4 more
doaj   +1 more source

Correction: M6A associated TSUC7 inhibition contributed to Erlotinib resistance in lung adenocarcinoma through a notch signaling activation dependent way. [PDF]

J Exp Clin Cancer Res, 2023
Li K, Peng ZY, Gao S, Wang QS, Wang R, Li X, Xiao GD, Zhang J, Ren H, Tang SC, Sun X.   +10 more
europepmc   +1 more source

IL-8 signaling is involved in resistance of lung carcinoma cells to erlotinib

Oncotarget, 2016
A signaling pathway that is frequently deregulated in human carcinomas and has been explored as a therapeutic target involves the activation of the epidermal growth factor receptor (EGFR). Inhibition of EGFR via the small molecule inhibitors erlotinib and gefitinib commonly results in tumor resistance, even in patients with EGFR-mutant tumors that ...
Fernando, Romaine I., Hamilton, Duane H., Dominguez, Charli, David, Justin M., McCampbell, Kristen K., Palena, Claudia   +5 more
openaire   +3 more sources

[Retracted] Exosome‑mediated transfer of lncRNA RP11‑838N2.4 promotes erlotinib resistance in non‑small cell lung cancer. [PDF]

Int J Oncol, 2023
Zhang W, Cai X, Yu J, Lu X, Qian Q, Qian W.   +5 more
europepmc   +1 more source